Toshio Fujino 研究室

主宰者：Toshio Fujino

近畿大学

AI 要約（直近 5 年の研究成果）

肺がんなどの悪性腫瘍の治療において、特定の遺伝子変異を標的とする分子標的薬の開発と評価を主要なテーマとしている研究室です。特に、表皮成長因子受容体（EGFR）やMET、ALKといったがん関連遺伝子の変異に対する薬剤感受性を調べ、既存の治療薬に対する耐性機序を解明することに取り組んでいます。研究手法としては、遺伝子改変細胞株を用いた細胞培養実験から、患者由来の細胞やがん組織を用いたより実臨床に近い評価系まで、多層的なアプローチを採用しています。具体的には、特定の遺伝子変異を持つ細胞を培養して薬剤の増殖抑制効果を測定したり、患者から採取したがん組織をマウスに移植して薬剤の有効性を評価したり、患者血液中の腫瘍由来DNAを分析したりする研究を行っています。さらに、肺がんの予後因子に関する臨床統計解析や、新規に開発中の治療薬の臨床試験データ分析も実施しています。これらの研究を通じて、既存薬に対する耐性メカニズムの同定や、耐性獲得後に有効な次世代的治療薬候補の発掘を進めており、難治性がん患者に対する新しい治療戦略の開発に貢献することを目指しています。

※ AI（Claude）が、公開されている論文要旨から研究の問い・手法・主要な発見を事実情報として抽出・再構成して自動生成しています。誤りを含む可能性があるため、正確性は研究室公式情報でご確認ください。

外部リンク

研究成果（33 件）

[2025] Figure S1 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30708700
[2025] Figure S4 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30708688
[2025] Supplementary tables 1 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30708664
[2025] Figure S9 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30708670
[2025] Supplementary Data 1 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30708667
[2025] Figure S8 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30708673
[2025] Figure S7 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30708676
[2025] Figure S3 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30708691
[2025] Figure S5 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30708685
[2025] Figure S2 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30708694

続きを表示（残り 23 件）

[2025] Figure S6 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30708679
[2025] Figure S10 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30708697
[2025] Efficacy of Conventional and Novel Tyrosine Kinase Inhibitors for Uncommon EGFR Mutations—An In Vitro Study
DOI: https://doi.org/10.3390/cells14171386
[2025] 290 | REAL‐WORLD SAFETY AND EFFICACY OF POLA‐R‐CHP IN PATIENTS WITH PREVIOUSLY UNTREATED DLBCL: ANALYSIS OF 500 PATIENTS IN THE POLASTAR STUDY
DOI: https://doi.org/10.1002/hon.70094_290
[2024] NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
DOI: https://doi.org/10.1158/2159-8290.cd-24-0231
[2023] Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion
DOI: https://doi.org/10.1016/j.jtho.2023.08.029
[2023] Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug Testing
DOI: https://doi.org/10.1016/j.jtocrr.2023.100554
[2023] BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.ccr-22-3901
[2022] SY20-4 Treatment strategy of lung cancer with MET, NTRK and BRAF gene aberrations: Insights from in vitro and clinical data
DOI: https://doi.org/10.1016/j.annonc.2022.05.479
[2022] Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation
DOI: https://doi.org/10.1186/s13045-022-01299-z
[2022] Presence of a Ground-Glass Opacity Component Is the True Prognostic Determinant in Clinical Stage I NSCLC
DOI: https://doi.org/10.1016/j.jtocrr.2022.100321
[2021] In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial
DOI: https://doi.org/10.1016/j.lungcan.2021.10.014
[2021] Frequent EGFR Mutations and Better Prognosis in Positron Emission Tomography-Negative, Solid-Type Lung Cancer
DOI: https://doi.org/10.1016/j.cllc.2021.10.003
[2021] P68.12 Inter-Tumor Heterogeneity of CD44 Expression in Non-Small Cell Lung Cancers / EGFR Mutated Lung Adenocarcinomas
DOI: https://doi.org/10.1016/j.jtho.2021.08.699
[2021] Intra-tumor and Inter-tumor Heterogeneity in MET Exon 14 Skipping Mutations and Co-mutations in Pulmonary Pleomorphic Carcinomas
DOI: https://doi.org/10.1016/j.cllc.2021.09.005
[2021] Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study
DOI: https://doi.org/10.21037/tlcr-21-216
[2021] KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments
DOI: https://doi.org/10.1016/j.jtho.2021.04.015
[2021] Activity of <scp>tarloxotinib‐E</scp> in cells with <scp><i>EGFR</i></scp> exon‐20 insertion mutations and mechanisms of acquired resistance
DOI: https://doi.org/10.1111/1759-7714.13931
[2021] Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
DOI: https://doi.org/10.1016/j.jtocrr.2020.100134
[2021] P86.05 In Vitro Validation Study for HER2 Mutations Identified in Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial
DOI: https://doi.org/10.1016/j.jtho.2021.01.1234
[2021] P76.71 RYK Confers Drug Tolerance to Osimertinib in Lung Cancer Cells with EGFR Mutations
DOI: https://doi.org/10.1016/j.jtho.2021.01.1128
[2021] The prevalence and risk factors associated with preoperative deep venous thrombosis in lung cancer surgery
DOI: https://doi.org/10.1007/s00595-021-02243-3
[2021] Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancer
DOI: https://doi.org/10.1016/j.lungcan.2021.02.017

科研費（0 件）

まだデータがありません（KAKEN 取り込み後に表示）。

所属学会・役職（0 件）

まだデータがありません（学会データ連携後に表示）。

AI 要約（直近 5 年の研究成果）

外部リンク

関連研究室(8 件)

研究成果（33 件）

科研費（0 件）

所属学会・役職（0 件）